Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
Anticancer Res. 2010 Nov;30(11):4767-8.
Growing evidence points toward the key role of angiogenesis in ovarian cancer. Granulosa cell tumor (GCT) does not seem to be an exception. Recent studies reporting the use of bevacizumab, a monoclonal antibody against the vascular epithelial growth factor, in recurrent GCT have shown encouraging results in terms of both symptoms control and response rate. This study presented the case of an adult-type GCT treated with neoadjuvant bevacizumab. To the best of the Authors' knowledge, this is the first report describing the use of an anti-angiogenic agent as neoadjuvant therapy in GCT. A further discussion on the results of this study and those previously published is also given.
越来越多的证据表明血管生成在卵巢癌中起着关键作用。颗粒细胞瘤（GCT）似乎也不例外。最近有研究报告称，在复发性 GCT 中使用贝伐单抗（一种针对血管内皮生长因子的单克隆抗体），在控制症状和缓解率方面均取得了令人鼓舞的结果。本研究介绍了一例接受新辅助贝伐单抗治疗的成人型 GCT。据作者所知，这是首例描述将抗血管生成药物作为 GCT 新辅助治疗的报告。本文还进一步讨论了这项研究及之前发表的研究结果。
